vendredi 16 mars 2018

Onco Actu du 16 mars 2018

Pour info : la parution de ce bulletin s'interrompt pendant une semaine. 
De retour le lundi 26 mars...

1. Biologie

How Editing RNA—Not DNA—Could Cure Disease in the Future [Gizmodo]

Mutating DNA caught on film [Science]

2.5 Etiologie - Gènes

Matter: What’s Behind Many Mystery Ailments? Genetic Mutations, Study Finds [NY Times]

3.1 Prévention - Tabac

FDA Advances Plan To Slash Nicotine In Cigarettes [NPR]

FDA begins anti-smoking push to cut nicotine in cigarettes [STAT]

FDA takes fresh step towards curbing U.S. nicotine addiction [Reuters]

FDA moves ahead with ‘historic’ plan to reduce nicotine in cigarettes [Washington Post]

How Could Lowering Nicotine Levels in Cigarettes Change the Future of Public Health? [FDA]

In a first, the FDA announces its intention to reduce the amount of nicotine allowed in cigarettes [LA Times]

4.1 Dép., diag. & prono. - Prostate

PSA testing for prostate cancer is only worth it for some [The Conversation]

4.12 Biopsies liquides

Improved capture of cancer cells could aid in disease tracking [UNC]

4.2 Dép., diag. & prono. - Génome

Genetic tests ordered by doctors race to market, while ‘direct-to-consumer’ tests hinge on FDA approval [STAT]

NHS doctors need more support to deliver genomic medicine to patients, says Cambridge think-tank [PHG Foundation]

5.12.2 Immunothérapies - CAR-T

Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cells [Adaptimmune]

Adaptimmune shares boosted by new signs of success with TCR cell therapy [EndPoints]

5.12.8 Immunothérapies - Economie

GV, Roche help Ideaya to $94M crossover round, setting stage for synthetic lethality, I-O trials [FierceBiotech]

Hinting at an IPO and big things ahead for synthetic lethality, preclinical Ideaya touts a $94M round [EndPoints]

5.2 Pharma

MorphoSys eyes MOR208 approval after midphase DLBCL data impress [FierceBiotech]

Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (Cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma [Exelixis]

Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer [Janssen]

J&J’s blockbuster hopeful erdafitinib gets ‘breakthrough’ moniker [EndPoints]

5.4 Traitements - Economie

The Imperative of Addressing Cancer Drug Costs and Value [NCI]

5.9 AACR

AACR Previews Research from Annual Meeting 2018 [Cancer Research Catalyst]

6.6 Publications

“The ‘1’ key was not pressed hard enough:” Did a typo kill a cancer paper? [Retraction Watch]

Are research papers less accurate and truthful than in the past? [The Economist]